Patents by Inventor Irving M. London

Irving M. London has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating sickle cell disease
    Patent number: 6051402
    Abstract: Gene therapy methods and compositions for high level expression of anti-sickling globin proteins in erythroid cells for treating Sickle Cell disease are described.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: April 18, 2000
    Assignee: Massachusetts Institute of Technology
    Inventors: Philippe LeBoulch, Irving M. London
  • Compositions and methods for treating sickle cell disease
    Patent number: 5861488
    Abstract: Gene therapy methods and compositions for high level expression of anti-sickling globin proteins in erythroid cells for treating Sickle Cell disease are described.
    Type: Grant
    Filed: September 23, 1997
    Date of Patent: January 19, 1999
    Assignee: Massachusetts Institute of Technology
    Inventors: Philippe LeBoulch, Irving M. London
  • DNA encoding the heme-regulated eukaryotic initiation factor 2.alpha. kinase
    Patent number: 5690930
    Abstract: The cDNA which encodes heme-regulated eIF-2.alpha. kinase (HRI) has been cloned from a lambda Zap II cDNA library of rabbit reticulocytes. The rabbit HRI cDNA is highly homologous to human HRI and hybridizes to the human HRI DNA under moderately stringent conditions. The rabbit HRI cDNA contains 2729 amino acids. In vitro translation of HRI mRNA transcribed from HRI cDNA yields a 90 kDa polypeptide with eIF-2.alpha. kinase activity. Since HRI is a potent inhibitor of protein synthesis, it is anti-proliferative in nature. In addition, the unusually high degree of homology of HRI to three protein kinases involved in the regulation of cell division suggests that HRI plays a direct role in the regulation of cell division.
    Type: Grant
    Filed: April 10, 1996
    Date of Patent: November 25, 1997
    Assignee: Massachusetts Institute of Technology
    Inventors: Jane-Jane Chen, Irving M. London
  • Retroviral vectors for transducing .beta.-globin gene and .beta.-locus control region derivatives
    Patent number: 5631162
    Abstract: A process and means for the design and the optimization of retroviral vectors transducing human .beta.-globin gene and .beta.-Locus Control Region (.beta.-LCR) derivatives, hereafter referred to as [.beta.-globin/LCR] retroviruses, which successfully meet the following criteria required for gene therapy applications: (1) stability of proviral transmission (low frequency of rearrangements similar to retroviral vectors considered stable in the art) upon infection of cell-lines and murine bone marrow cells, (2) improved viral titer, thereby allowing successful infection of bone marrow cells, and (3) high erythroid expression of the transduced human .beta.-globin gene, are described, along with specific constructs.
    Type: Grant
    Filed: June 11, 1993
    Date of Patent: May 20, 1997
    Assignee: Massachusetts Institute of Technology
    Inventors: Philippe LeBoulch, Irving M. London, Dorothy Tuan
  • DNA encoding the heme-regulated eukaryotic initiation factor 2.alpha. kinase
    Patent number: 5525513
    Abstract: The cDNA which encodes heme-regulated eIF-2.alpha. kinase (HRI) has been cloned from a lambda Zap II cDNa of rabbit reticulocytes. The rabbit HRI cDNA is highly homologous to human HRI and hybridizes to the human HRI DNA under moderately stringent conditions. The rabbit HRI cDNA contains 2729 amino acids. In vitro translation of HRI mRNA transcribed from HRI cDNA yields a 90 kDa polypeptide with eIF-2.alpha. kinase activity. Since HRI is a potent inhibitor or protein synthesis, it is anti-proliferative in nature. In addition, the unusually high degree of homology of HRI to three protein kinases involved in the regulation of cell division suggests that HRI plays a direct role in the regulation of cell division.
    Type: Grant
    Filed: August 31, 1992
    Date of Patent: June 11, 1996
    Assignee: Massachusetts Institute of Technology
    Inventors: Jane-Jane Chen, Irving M. London
  • Human erythroid-specific transcriptional enhancer
    Patent number: 5126260
    Abstract: A human erythroid specific enhancer element is described. The enhancer element can be used to enhance transcription of a structural gene in erythroid cells. Methods for gene therapy employing the enhancer element are also disclosed.
    Type: Grant
    Filed: December 4, 1990
    Date of Patent: June 30, 1992
    Assignee: Massachusetts Institute of Technology
    Inventors: Dorothy Y. H. Tuan, Irving M. London, William B. Solomon